X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs NOVARTIS - Comparison Results

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA NOVARTIS NATCO PHARMA/
NOVARTIS
 
P/E (TTM) x 19.9 300.3 6.6% View Chart
P/BV x 19.0 25.6 74.4% View Chart
Dividend Yield % 0.6 1.4 42.2%  

Financials

 NATCO PHARMA   NOVARTIS
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
NOVARTIS
Mar-17
NATCO PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs877855 102.6%   
Low Rs424666 63.6%   
Sales per share (Unadj.) Rs223.4219.0 102.0%  
Earnings per share (Unadj.) Rs31.119.1 162.7%  
Cash flow per share (Unadj.) Rs40.320.3 198.4%  
Dividends per share (Unadj.) Rs5.0010.00 50.0%  
Dividend yield (eoy) %0.81.3 58.5%  
Book value per share (Unadj.) Rs219.5307.0 71.5%  
Shares outstanding (eoy) m33.0729.96 110.4%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.93.5 83.8%   
Avg P/E ratio x20.939.8 52.6%  
P/CF ratio (eoy) x16.137.5 43.1%  
Price / Book Value ratio x3.02.5 119.6%  
Dividend payout %16.152.4 30.7%   
Avg Mkt Cap Rs m21,50422,779 94.4%   
No. of employees `000NA0.7 0.0%   
Total wages/salary Rs m1,1281,393 81.0%   
Avg. sales/employee Rs ThNM9,736.2-  
Avg. wages/employee Rs ThNM2,066.8-  
Avg. net profit/employee Rs ThNM849.0-  
INCOME DATA
Net Sales Rs m7,3896,562 112.6%  
Other income Rs m167702 23.8%   
Total revenues Rs m7,5567,264 104.0%   
Gross profit Rs m1,793259 692.7%  
Depreciation Rs m30436 847.9%   
Interest Rs m3667 5,086.1%   
Profit before tax Rs m1,290917 140.6%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m309345 89.5%   
Profit after tax Rs m1,027572 179.6%  
Gross profit margin %24.33.9 615.2%  
Effective tax rate %23.937.6 63.6%   
Net profit margin %13.98.7 159.5%  
BALANCE SHEET DATA
Current assets Rs m3,6819,731 37.8%   
Current liabilities Rs m3,1231,830 170.6%   
Net working cap to sales %7.6120.4 6.3%  
Current ratio x1.25.3 22.2%  
Inventory Days Days8949 183.8%  
Debtors Days Days5925 233.3%  
Net fixed assets Rs m7,68557 13,435.7%   
Share capital Rs m331141 235.0%   
"Free" reserves Rs m6,6709,056 73.7%   
Net worth Rs m7,2599,196 78.9%   
Long term debt Rs m9550-   
Total assets Rs m11,95711,499 104.0%  
Interest coverage x4.5128.4 3.5%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.60.6 108.3%   
Return on assets %11.75.0 231.3%  
Return on equity %14.26.2 227.5%  
Return on capital %20.710.1 206.2%  
Exports to sales %39.40-   
Imports to sales %5.70-   
Exports (fob) Rs m2,908NA-   
Imports (cif) Rs m421NA-   
Fx inflow Rs m3,445129 2,672.9%   
Fx outflow Rs m7031,734 40.5%   
Net fx Rs m2,743-1,605 -170.9%   
CASH FLOW
From Operations Rs m1,440-380 -379.5%  
From Investments Rs m-1,0894,208 -25.9%  
From Financial Activity Rs m-353-3,318 10.6%  
Net Cashflow Rs m-1510 -0.3%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 1.5 75.0 2.0%  
Indian inst/Mut Fund % 7.8 2.0 392.0%  
FIIs % 16.6 1.6 1,039.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 21.5 120.9%  
Shareholders   25,395 41,647 61.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   BIOCON LTD  CADILA HEALTHCARE  SUVEN LIFE  PLETHICO PHARMA  GLENMARK PHARMA  

Compare NATCO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Metal & Realty Stocks Fall(Closing)

Indian share markets ended lower today amid weak global cues. At the closing bell, the BSE Sensex finished lower by 262 points.

Related Views on News

NATCO PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 69.6%

May 25, 2018 | Updated on May 25, 2018

For the quarter ended March 2018, NATCO PHARMA has posted a net profit of Rs 3 bn (up 69.6% YoY). Sales on the other hand came in at Rs 8 bn (up 32.9% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Jun 19, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - WYETH LTD COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS